2026-09-08
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 artivabio.com ↗
2026-06-08
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today artivabio.com ↗
2026-05-19
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases artivabio.com ↗
2026-05-08
Artiva Biotherapeutics, Inc.
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 artivabio.com ↗
2026-01-21
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL artivabio.com ↗
2025-11-12
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease artivabio.com ↗
2025-11-03
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® artivabio.com ↗
2025-05-13
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting artivabio.com ↗
2025-04-28
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting artivabio.com ↗
2024-04-17
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis artivabio.com ↗
2024-02-22
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis artivabio.com ↗
2023-08-16
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis artivabio.com ↗
2023-05-25
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting artivabio.com ↗
2023-04-26
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting artivabio.com ↗
2023-01-31
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101 artivabio.com ↗
2022-11-10
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting artivabio.com ↗
2022-11-03
Artiva Biotherapeutics, Inc.
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101 artivabio.com ↗
2022-10-05
Artiva Biotherapeutics, Inc.
Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting artivabio.com ↗
2020-12-07
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas artivabio.com ↗
Show 7 more releases